QIAGEN (QGEN) said late Tuesday it has received clearance from the US Food and Drug Administration for the use of its gastrointestinal panels on the QIAstat-Dx Rise automated syndromic testing system.
Following the health regulator's approval, laboratories in the US can run respiratory and gastrointestinal panels on the higher-throughput automated platform, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.